Topic: Management of Hepatocellular Carcinoma

Download All Articles

A special issue of Hepatoma Research  (Print ISSN:2394-5079; Online ISSN:2454-2520).

Deadline for manuscript submissions: 31 Aug 2018

Share This Special Issue

Guest Editor(s)

  • Osamu Yokosuka, MD
    Chiba University, Department of Medicine and Clinical Oncology, Chiba, Japan.

    E-mail

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.editorialmanager.com/hres/default.aspx
Submission Deadline: 31 Aug, 2018
Contacts: Siqi Li, Assistant Editor, editor001@hrjournal.net

Published Articles Download All Articles
  • Minimally invasive therapies for hepatocellular carcinoma: narrowing the gaps

    Kevin M. Sullivan , Raymond S. Yeung
    With increasing awareness of the HCC epidemic around the globe, early diagnosis of tumors provides a greater opportunity to benefit patients from liver-directed treatments including surgical resection, ablation, catheter-based therapies and external beam radiation. Development of new approaches and refinement of existing techniques have improved our capabilities to provide efficacious and safe... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:68. | doi:10.20517/2394-5079.2018.95
    Published on: 25 Oct 2018  | Viewed:400  | Downloaded:17
    +HTML| PDF
  • Endolymphatic immunotherapy for advanced hepatocellular carcinoma: an update of our experience

    Marialuisa Lugaresi , Yuval Katz , Riccardo Bertelli , Noa Ruhrman , Lorenza Puviani , Giuseppe Cavallari , Caterina De Vinci , Giancarlo Pizza , Bruno Nardo
    Aim: We report an update of our experience on endolymphatic immunotherapy in patients with advanced hepatocellular carcinoma (HCC) not eligible for surgery. Methods: From 2003 to 2009 we enrolled 39 patients with advanced HCC not suitable for surgery. Patients underwent monthly endolymphatic injections of 1.5 × 106-3.0 × 106 IL-2-activated peripheral autologous lymphocytes and 250U of IL-2.... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:67. | doi:10.20517/2394-5079.2018.88
    Published on: 18 Oct 2018  | Viewed:295  | Downloaded:9
    +HTML| PDF
  • New and old biomarkers of hepatocellular carcinoma

    Georgios Zacharakis , Ahmad Aleid , Khaled K Aldossari
    Hepatocellular carcinoma (HCC) is a significant cause of mortality in patients with chronic liver disease around the world. Development of biomarkers for early HCC detection is a primary public health goal to decrease mortality. The ideal biomarkers should be highly sensitive and specific for surveillance of high-risk populations and early detection of HCC and also be able to predict... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:65. | doi:10.20517/2394-5079.2018.76
    Published on: 17 Oct 2018  | Viewed:507  | Downloaded:56
    +HTML| PDF
  • Alpha-fetoprotein as a predictor of hepatocellular carcinoma recurrence following liver transplantation

    Evangelia M. Fatourou , Abid R. Suddle , Michael A. Heneghan
    Alpha-fetoprotein (AFP) has been increasingly recognised as a valuable marker in predicting HCC recurrence post-liver transplantation. Moreover, its secretion has been associated with poor histological tumour characteristics as it reflects an aggressive tumour biological behaviour. This review aims to summarise the emerging evidence on the use of AFP either as an independent marker, or as a... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:63. | doi:10.20517/2394-5079.2018.62
    Published on: 10 Oct 2018  | Viewed:560  | Downloaded:32
    +HTML| PDF
  • Liver transplantation for hepatocellular carcinoma - non-cancer factors and implications for improving outcome beyond standard tumor criteria

    Arno Kornberg , Martina Schernhammer
    Liver transplantation (LT) is recognized as best treatment option in patients with early hepatocellular cancer (HCC) in underlying liver cirrhosis. Apart from tumor size and number implemented in the Milan criteria, which are current worldwide standards for patient selection, several biological tumor factors have been identified to affect cancer-specific outcome. In particular, grading and... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:60. | doi:10.20517/2394-5079.2018.86
    Published on: 29 Sep 2018  | Viewed:519  | Downloaded:19
    +HTML| PDF
  • Novel diagnosis and therapy for hepatoma targeting HBV-related carcinogenesis through alternative splicing of FIR (PUF60)/FIRΔexon2

    Kazuyuki Matsushita , Tyuji Hoshino
    Aim: Disturbed alternative splicing of far upstream element-binding protein-interacting repressor (FIR) was found to be unable to repress c-Myc transcription and so it might be important for suppressing tumor development. FIR is a splicing variant of poly (U)-binding-splicing factor (PUF60), and forms complex with other splicing factors. FIR/PUF60 is a splicing factor of U2 small nuclear... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:61. | doi:10.20517/2394-5079.2018.81
    Published on: 29 Sep 2018  | Viewed:639  | Downloaded:30
    +HTML| PDF
  • Staging of hepatocellular carcinoma

    Sedat Karademir
    Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths in the world. In contrast to other cancers, survival of patients with HCC is determined by the extent of the tumor in addition to underlying liver disease and its functional reserve. From risk factors to management, HCC reveals a considerable geographic and institutional variation throughout the world. Although many... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:58. | doi:10.20517/2394-5079.2018.40
    Published on: 26 Sep 2018  | Viewed:421  | Downloaded:21
    +HTML| PDF
  • Adult African Americans undergoing cadaveric liver transplantation for hepatocellular carcinoma within the Milan criteria have the lowest 5-year survival among all the ethnic groups in the United States: analysis of USA national data between January 2002

    Michele Molinari , Subhashini Ayloo , Allan Tsung , Patrick Bou Samra , Naudia Jonaissaint
    Aim: To investigate the potential effects of recipient ethnicity on the short and long-term outcomes of patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) in the United States. We performed a retrospective study using the standard transplant analysis and research (STAR) files with the primary aim of assessing short and long-term survival of different ethnic groups... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:56. | doi:10.20517/2394-5079.2018.71
    Published on: 20 Sep 2018  | Viewed:290  | Downloaded:15
    +HTML| PDF
  • Thermal ablation of large unresectable hepatocellular carcinoma in cirrhotic patients

    Giovan Giuseppe Di Costanzo , Raffaella Tortora , Anna Opramolla , Marco Guarracino
    Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Surgery is the mainstay of treatment, but less than 20%-30% of patients are good candidates. Actually, thermal ablation is considered the best treatment with curative intent for cirrhotic patients with unresectable HCC ≤ 3 cm. Unfortunately, radio frequency efficacy in obtaining the complete ablation of... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:53. | doi:10.20517/2394-5079.2018.56
    Published on: 17 Sep 2018  | Viewed:241  | Downloaded:24
    +HTML| PDF
  • Cancer immunotherapy for hepatocellular carcinoma

    Joo-Ho Lee , Soo-Yeon Oh , Jin Yong Kim , Naoshi Nishida
    Most hepatocellular carcinomas (HCCs) arise on a background of chronically inflamed liver, and thus are considered typical immunogenic cancers. Although there have been advances in treatment options for HCC, many patients still struggle with a limited chance of survival requiring further innovative approach. Especially for the advanced HCC, many other molecular targeted therapies had been... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:51. | doi:10.20517/2394-5079.2018.78
    Published on: 10 Sep 2018  | Viewed:599  | Downloaded:53
    +HTML| PDF
  • Hepatic resection for hepatocellular carcinoma

    Shun Yamaguchi , Taichiro Kosaka , Susumu Eguchi
    Hepatic resection has become the standard treatment of primary liver cancer. Indications for hepatic resection in patients with hepatocellular carcinoma (HCC) vary greatly between Japan and other countries because the clinical practice guidelines for HCC defined by the Japan Society of Hepatology differ from the EASL-EORTC clinical practice guidelines. Hepatic resection is not recommended as a... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:50. | doi:10.20517/2394-5079.2018.68
    Published on: 22 Aug 2018  | Viewed:749  | Downloaded:55
    +HTML| PDF
  • Hypofractionated ablative radiation therapy for hepatocellular carcinoma: practical considerations and review of the literature

    Marsha Reyngold , Eugene J. Koay , Christopher H. Crane
    Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. The prognosis for patients who present with inoperable primary liver tumors is poor with median survival times of 12 months or less. Tumor-related liver failure is a common cause of mortality, underscoring the importance of local control. Recent advancements in external beam radiation therapy delivery techniques have... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:49. | doi:10.20517/2394-5079.2018.84
    Published on: 20 Aug 2018  | Viewed:972  | Downloaded:80
    +HTML| PDF
  • Laparoscopic liver resection for hepatocellular carcinoma

    Massimo Giacca , Daniel Cherqui
    Hepatocellular carcinoma (HCC) represents the most common indication of laparoscopic liver resection (LLR). It must be acknowledged that most series concern minor hepatectomies for peripheral lesions located in favorable segments, and such procedures are now performed in the majority of HPB centers. However, there are growing reports concerning major hepatectomies (i.e., 3 segments or more) and... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:47. | doi:10.20517/2394-5079.2018.79
    Published on: 17 Aug 2018  | Viewed:497  | Downloaded:35
    +HTML| PDF
  • Exosome-based liquid biopsy in the management of hepatocellular carcinoma

    Aparna Jayachandran , Sasidhar Venkata Manda , Ritu Shrestha , Kim R. Bridle , Prashanth Prithviraj , Darrell H. G. Crawford
    Hepatocellular carcinoma (HCC) commonly presents at an advanced stage due to the lack of efficient early screening tools. Early, non-invasive biomarkers useful in the diagnosis and prognosis of HCC would be of significant benefit for HCC management. Development of exosome-based liquid biopsy as a non-invasive method for the management of HCC has gained much traction. Exosomes are small... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:44. | doi:10.20517/2394-5079.2018.59
    Published on: 13 Aug 2018  | Viewed:626  | Downloaded:77
    +HTML| PDF
  • Living donor liver transplantation for patients with hepatocellular carcinoma in Japan

    Yasuhiko Sugawara , Hidekazu Yamamoto , Taizo Hibi
    Liver transplantation has now been an established treatment for hepatocellular carcinoma and cirrhosis. The Milan criteria have been accepted and applied widely in the world as an indication for deceased donor liver transplant. Due to the severe organ shortage, however, living donor liver transplant (LDLT) has accounted for the majority of transplantations in Japan and the other Asian... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:33. | doi:10.20517/2394-5079.2018.69
    Published on: 10 Jul 2018  | Viewed:312  | Downloaded:17
    +HTML| PDF
  • Hepatocellular carcinoma in patients without cirrhosis: relevance and clinical characteristics

    Kellyane Santana Dias Carvalho , Luciano E. Fonseca , Helma P. Cotrim
    Aim: The present study evaluated the frequency of hepatocellular carcinoma (HCC) in patients without cirrhosis. Methods: HCC patients were recruited from two reference centers for liver disease in Northeast Brazil from 2010 to 2016. The diagnosis of HCC and cirrhosis was based on international criteria.Results: A total of 169 patients were included, and 16% (27) of the patients did not have... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:15. | doi:10.20517/2394-5079.2018.13
    Published on: 29 May 2018  | Viewed:613  | Downloaded:53
    +HTML| PDF
  • Systemic therapies for hepatocellular carcinoma: a recap of the current status

    Petros Giovanis , Manuela De Bona , Fabio Farinati , Andrea Buda , Riccardo Berletti , Fable Zustovich , Simona D’Ippolito , Michele De Boni , Umberto Cillo , Davide Pastorelli
    After decades of frustrating nihilism due to lack of innovative therapeutic solutions, the onco-hepatological community is facing up to important novelties for the treatment of intermediate and advanced stages of liver cancer. Four new drugs have been investigated and resulted in positive data: lenvatinib resulted not inferior to the standard of care sorafenib in first line, regorafenib and... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:10. | doi:10.20517/2394-5079.2018.21
    Published on: 27 Apr 2018  | Viewed:1499  | Downloaded:137
    +HTML| PDF
  • A potential clinical based score in hepatitis C virus cirrhotic patients to exclude small hepatocellular carcinoma

    Denise Cerqueira Paranaguá-Vezozzo , Celso Eduardo Lourenço Matielo , Daniel Ferraz de Campos Mazo , Lucas Souto Nacif , Mario Guimaraes Pessoa , Gleicy Luz Reinoso Pereira , Roque Gabriel Rezende de Lima , Patricia Momoyo Yoshimura Zitelli , Suzane Kioko Ono , Flair José Carrilho
    Aim: Hepatitis C virus (HCV) cirrhosis is an important cause of hepatocellular carcinoma (HCC). This study aimed to identify factors of HCC presence among HCV cirrhotic patients with and without small diameter HCC (≤ 3 cm). Methods: A case control transversal study between 1998 and 2003 including 93 patients: 31 with small diameter HCC and 62 without HCC. Groups were matched by age and gender.... Read more
    This article belongs to the Special Issue Management of Hepatocellular Carcinoma
    Hepatoma Res 2018;4:11. | doi:10.20517/2394-5079.2018.17
    Published on: 27 Apr 2018  | Viewed:979  | Downloaded:78
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.